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Predictors of clinical outcomes after 
periodontal treatment of aggressive 
periodontitis: 12-month randomized trial
Abstract: Little is known about the factors that may be used in clinical 
practice to predict the therapeutic response of aggressive periodontitis 
patients. The aim of this study was to determine predictors of clinical 
outcomes after non-surgical treatment of aggressive periodontitis. A 
total of 24 patients (aged 13-26 years) received oral hygiene instructions, 
as well as subgingival scaling and root planing. Twelve subjects received 
systemic azithromycin at random. Clinical variables were assessed at 
baseline, 3, 6, 9, and 12 months. Baseline microbiological assessment was 
performed by checkerboard DNA-DNA hybridization. Multivariable 
models used generalized estimating equations. There were significant 
improvements in the entire sample in regard to pocket depth, clinical 
attachment level and bleeding on probing. Significant predictors of a 
reduction in mean pocket depth were: use of azithromycin, non-molar 
teeth, generalized disease and baseline pocket depth. Absence of plaque 
predicted a 0.22 mm higher attachment gain, whereas a baseline pocket 
depth ≥7 mm predicted a 1.36 mm higher attachment loss. Azithromycin, 
plaque, and baseline pocket depth were significant predictors of bleeding 
on probing. The concomitant presence of all three red complex species 
predicted a 0.78 mm higher attachment loss. It may be concluded that 
dental plaque, tooth type, disease extent, baseline pocket depth, and use 
of azithromycin were significant predictors of the clinical response to 
treatment for aggressive periodontitis in young individuals. Moreover, 
the presence of multiple periodontal pathogens may predict challenges 
in achieving a favorable outcome for aggressive periodontitis.
Keywords: Aggressive Periodontitis; Prognosis; Anti-Bacterial 
Agents; Microbiology.
Introduction
Although the prevalence of aggressive periodontitis (AgP) is lower 1,2 than 
that of chronic periodontitis, it still represents a challenge in periodontal 
practice.3 Studies have shown that periodontal treatment results in mixed 
clinical outcomes.4,5 Moreover, little is known about the factors that may 
contribute to a favorable outcome following periodontal treatment of 
AgP. Furthermore, the evidence available on treatment outcomes has 
been provided primarily by uncontrolled studies and short follow-ups.
Only two long-term interventional studies have evaluated prognostic 
factors among subjects with AgP.6,7 One study7 involving 25 AgP patients 
Declaration of Interests: The authors 
certify that they have no commercial or 
associative interest that represents a conflict 
of interest in connection with the manuscript.
Corresponding Author:
Alex Nogueira Haas 
e-mail: alexnhaas@gmail.com
DOI: 10.1590/1807-3107BOR-2016.vol30.0041
Submitted: Jul 29, 2015 
Accepted for publication: Oct 27, 2015 
Last revision: Dec 17, 2015
1Braz Oral Res [online]. 2016;30(1):e41
Predictors of clinical outcomes after periodontal treatment of aggressive periodontitis: 12-month randomized trial 
found that smoking, stress and counts of Porphyromonas 
gingivalis and Treponema denticola were significantly 
associated with disease progression. The other6 
demonstrated that smoking and gingival bleeding 
were significantly associated with the progression 
of tissue loss. Tooth-related factors such as plaque,8,9 
tooth type8 and baseline pocket depth10 have also 
been studied as predictors of clinical outcomes after 
periodontal therapy in general and in AgP. These studies 
have provided useful overall information; however, 
prospective randomized studies with a greater follow-up 
may provide clinicians with stronger evidence on the 
predictability of periodontal treatment for AgP.
Given this scenario, clinicians are frequently 
uncertain about how AgP patients will respond to 
periodontal treatment, and, just as importantly, about 
what factors can predict clinical outcomes. The aim of 
this study was to assess the significance of patient- and 
tooth-related predictors of 12-month outcomes after 
nonsurgical periodontal treatment of AgP.
Methodology
Study sample
This study comprises a secondary analysis of a 
previously published randomized controlled trial. 
Detailed information about the study sample can be 
assessed in a previous publication of this randomized 
controlled trial.11
In brief, 24 AgP subjects, aged 13-26 years, 
with at least one incisor and one first molar with a 
periodontal probing depth (PPD) ≥4 mm, CA loss ≥4 
mm and bleeding on probing (BOP) were followed 
for 12 months in the present study. Individuals were 
recruited from the Periodontal Department of the 
Universidade Federal do Rio Grande do Sul - UFRGS, 
Porto Alegre, Brazil.
Interventions
Periodontal treatment consisted of two sessions 
at one-week intervals of supragingival scaling and 
oral hygiene instructions, followed by subgingival 
scaling and root planing (SRP) under local anesthesia 
performed within a period of 14 days by an experienced 
periodontist. Twelve randomly selected subjects 
were administered azithromycin in 500 mg tablets 
(EMS-SIGMA, São Paulo, Brazil) once daily for 3 days, 
whereas the other subjects were given placebo tablets.
The subjects were stratified by smoking status 
(smokers or nonsmokers) and disease extent (localized or 
generalized) to allow similar distribution of these factors 
in the sample. An assistant not involved in the study was 
responsible for the randomization of the participants 
within each stratum. Randomization was conducted 
by a draw. Test (azithromycin) and control (placebo) 
medications were stored in identical opaque-colored 
bottles identified only by the respective code of each 
participant. Randomization codes were kept by the same 
assistant and were revealed only after the statistical 
analyses had been performed. The periodontists involved 
in the treatment and in the clinical examination were 
masked to the study participants allocation throughout 
the experimental period.
The subjects took the first tablet just before the 
first session of SRP. After treatment, they were seen 
every three weeks for the first three months, then 
once a month for the next 3 to 6 months, and, lastly, 
once every three months in the last 6 months of the 
study. Recall visits included oral prophylaxis and 
oral hygiene instructions on an individualized basis.
Clinical examination
Visible plaque (VP), PPD, gingival recession (GR) 
and BOP were assessed in all participants at baseline 
and at 3, 6, 9, and 12 months after treatment. One 
calibrated periodontist, blinded for the use of antibiotics, 
performed all the measurements on six sites per tooth, 
excluding third molars. PPD and GR were assessed 
using a manual periodontal probe (CP10SE, HuFriedy, 
Chicago, USA). The CA level was calculated as the sum 
of probing depth and gingival recession. BOP was 
recorded as present/absent after PPD measurements.
Repeated measurements were performed on 12 
subjects to evaluate the examiner reproducibility, 
with at least one hour between each examination. 
The weighted kappa coefficients (1 mm) of PPD and 
CA loss were 0.92 and 0.85, respectively.
Sample size
The sample size was calculated based on the 
aims of the previous publication of this clinical 
trial.11 A sample size of 24 subjects was estimated 
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as needed to achieve an 80% power to detect a mean 
PPD difference of 1 mm (standard deviation 0.85) 
between the azithromycin and the placebo groups. 
A two-sided two-sample t-test with a significance 
level of 5% was used to calculate the sample size.
Microbiology
One pool of subgingival plaque was obtained 
for each participant at baseline. The supragingival 
plaque was removed, and subgingival samples were 
taken with sterile paper points from the deepest site 
of each tooth from all the teeth present. The samples 
were placed in Eppendorf tubes containing 1 ml of TE 
buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.6) and 
mixed vigorously to release bacterial cells from the 
paper points. The paper points were removed and the 
suspension was centrifuged and re-suspended in 150 
µl of TE. The samples were lysed by adding 150 µl of 
0.5 M NaOH and boiling for 10 minutes. Denatured 
DNA was neutralized with 800 µl of 5 M C2H3O2NH4 
and fixed in individual lanes on a nylon membrane 
(Hybond-N+, GE Healthcare Life Sciences, Piscataway, 
USA) using Minislot 30 (Immunetics, Cambridge, 
MA). The Miniblotter 45 apparatus (Immunetics) was 
used to hybridize 38 whole genomic DNA probes 
for 40 taxa of microorganisms. The probes were 
labeled with digoxigenin using the “Random Primer 
Digoxigenin Labeling Kit” (Roche Molecular Systems, 
Alameda, USA). DNA from serotypes a, b and c of 
A. actinomycetemcomitans was pooled in one probe. 
Samples were analyzed by the checkerboard DNA-
DNA hybridization technique,12 with modifications.
For the purpose of this study, the presence of 
six bacterial species at baseline was evaluated in 
prediction models. The three species comprising 
the red complex (Porphyromonas gingivalis, Tannerella 
forsythia and Treponema denticola), two species from 
the orange complex (Parvimonas micra and Prevotella 
intermedia) and Aggregatibacter actinomycetemcomitans 
were selected. Because of a h ighly skewed 
distribution of the data, microbial counts were 
analyzed as dichotomous variables. The presence 
of a specific species was determined using the 
cut-off point for detection of the checkerboard, 
established at 104 cells. Failure to detect a sign was 
recorded as zero.
Ethical aspects
The study protocol was approved by the Committee 
of Ethical Affairs of the School of Dentistry of the 
UFRGS. The subjects read and signed an informed 
consent before entering the study.
Statistical analysis
A total of 257 teeth presenting both CA loss ≥4 mm 
and PPD ≥4 mm at the baseline examination were 
included in the analyses. The mean number of teeth 
presenting these clinical characteristics by patient 
was 10.7 (standard deviation: 6.6; median=10.5 teeth). 
The worst affected site of each tooth was used in 
the analysis.
The following variables were assessed as possible 
predictors: age (years), gender (male/female), smoking 
status (nonsmoker/smoker), use of systemic antibiotic 
(placebo/azithromycin), tooth type (molar/non-molar), 
disease extent (localized/generalized), time elapsed 
from baseline (time points), visible plaque at each time 
point (absent/present: presence of visible plaque on 
at least one site per tooth), and baseline PPD category 
(4-6 mm/≥7 mm). The subjects were categorized into 
localized or generalized AgP as follows:13 subjects 
with at least one incisor or first molar with clinical 
attachment loss ≥4 mm and no more than two teeth 
other than the first molars or incisors were classified 
as having localized AgP, whereas those with three or 
more affected non-incisors/first molars were classified 
as having generalized AgP. Separate prediction 
models were fitted for each bacterial species and for 
an additional variable generated to describe the number 
of concomitant species from the red complex detected in 
each individual (1, 2 or 3 species). These microbiological 
models were adjusted for other predictors.
The outcomes of the present study included mean 
changes in PPD, CA level and BOP over 12 months. 
Crude comparisons of changes over time were made 
using commands that take into account clustering 
of teeth within individuals, with a robust variance 
estimator (Huber/White/sandwich estimator of 
variance). Wald-test adjusted p-values were used for 
multiple comparisons over time.
Multivariable analysis using generalized 
estimating equations (GEE) with exchangeable 
correlat ion structure and a robust variance 
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estimator was applied to evaluate the longitudinal 
effect of each predictor on PPD, CA loss and BOP, 
separately. GEE with Gaussian distribution and 
identity link was used. Univariable models were 
fitted, and predictors showing associations with 
p values ≤0.25 were entered in a multivariable 
model. Those predictors with non-significant 
associations (p ≥ 0.05) and demonstrating no 
confounding modification (at least 25% change in 
the other predictor estimates) were excluded from 
the final multivariable model. Interaction effects 
and multicollinearity were examined, and none 
were found to be statistically significant.
One subject from the placebo group moved out 
of town and missed the 12-month examination; 
a carry-forward strategy was employed for this 
individual, in order to account for the missing 
information, and the 9-month data were used 
following an intention-to-treat approach. Data 
analysis was performed using Stata software (Stata 14, 
Stata Corporation, College Station, USA).
Results
Twenty-eight individuals were screened for the 
study; however, 12 and 13 patients were randomized to 
the azithromycin and the placebo groups, respectively. 
One patient dropped out the study at the 3 month 
evaluation period for no specific reason, and was 
not included in the analysis (Figure 1). The sample 




Allocated intervention (N = 12)
Received allocated intervention (N = 12)
Excluded (N = 3)
Administration of antibiotics 
because of other conditions 
(2) and quit because of 
unknown reasons (1)
Randomized (N = 52





Lost to follow up/excluded
 from the analysis
Placebo group
Allocated intervention (N = 13)
Received allocated intervention (N = 13)
Figure 1. Flowchart of participation in the study
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initial PPD and CA loss were 6.5 mm (SE: 0.3) and 
5.8 mm (SE: 0.2), respectively. There was a significant 
reduction of 2.3 mm (SE: 0.2) in PPD and 48% in the 
extent of sites with BOP, from baseline to three months 
after treatment. The mean CA gain was 1.2 mm (SE: 0.2) 
after the three first months. These improvements 
endured throughout the 12-month period.
Figure 2 shows the pattern of unadjusted mean 
PPD over the 12-month follow-up period, according 
to disease extent, use of antibiotics, tooth type and 
baseline PPD. In the multivariable model, these 
predictors showed significant effects on PPD change 
(Table 2). The reduction in PPD during 12 months was 
0.58 mm higher in subjects with generalized versus 
localized AgP, 0.49 mm higher in subjects who had 
received adjunctive systemic azithromycin versus 
placebo, and 0.49 mm higher in non-molars versus 
molars. On the other hand, teeth with a baseline PPD 
≥7mm had a 1.32 mm higher PPD over time than 
teeth with a baseline PPD of 4-6 mm. Most of the 
PPD reduction occurred during the first 3 months 
post-treatment, and there were minimal changes in 
PPD at 6, 9 and 12 months follow-up.
Unadjusted mean CA level according to visible 
plaque and baseline PPD is shown in Figure 3. Changes 
in CA level were significantly associated with these 
two predictors (Table 3). Teeth with no visible plaque 
during a given follow-up examination had a 0.22 mm 
higher CA gain, on average, than teeth with dental 
plaque. Teeth with PPD ≥7 mm at baseline had a 
1.36 mm higher CA loss over 12 months than teeth 
with PPD 4-6 mm at baseline. The greatest amount of 
CA gain occurred in the first 3 months after treatment.
Presence of BOP was significantly associated with 
the use of azithromycin, plaque, baseline PPD and 
follow-up duration (Table 4). Use of azithromycin 
predicted a 14% reduction in the percentage of sites 
with BOP. Local factors such as tooth type and visible 
plaque accounted for small but significant contributions. 
Deep pockets at baseline predicted a 7% higher BOP 
than sites with baseline pockets of 4-6 mm.
None of the six bacterial species assessed in this 
study significantly predicted the changes in CA 
level, PPD and BOP during 12 months (Table 5). 
The presence of all three species of the red complex 
predicted a 0.78 mm higher CA loss over the 12 
months, compared with the presence of only one 
species (p = 0.02).
Discussion
The present study explored patient- and 
tooth-related factors, such as predictors of the clinical 
response to nonsurgical periodontal therapy among 
young individuals with AgP. Overall, the factors that 
consistently predicted clinical outcomes included 
disease extent, adjunctive use of azithromycin, tooth 
type, presence of visible plaque, and baseline level 
of PPD. Most of these variables showed statistically 
significant prediction of the reduction in PPD and 
BOP, whereas fewer variables showed significant 
predictions of CA gain.
Limited data exist on the wound healing of 
subjects with AgP; however, it appears from the 
literature that generalized AgP is more challenging 
to treat than localized AgP.3 Notably, in this study, 
subjects with generalized AgP showed greater PPD 
reduction than those with the localized form of the 
disease. We found no indication that this disparity 
may be attributed to differences in PPD at baseline 
between the groups (generalized: 6.59 ± 0.26 mm vs. 
localized: 6.20 ± 0.55 mm, p = 0.53). Reasons for this 
finding are still unknown and can only be speculated.
Table 1. Study sample characteristics at baseline
Variable Statistics Estimate
Age Years mean±SD 21.3±3.7
Gender Males
Females












n (%) 88 (34.2)
169 (65.8)
Visible plaque % sites mean±SD 71.5±29.8
PPD 
4-6 mm % teeth n (%) 127 (49.4)
≥7 mm % teeth n (%) 130 (50.6)
CAL
4-6 mm % teeth n (%) 180 (70.0)
≥7 mm % teeth n (%) 77 (30.0)
BOP % sites mean±SD 70.9±23.8
PPD: periodontal probing depth; CAL: clinical attachment level; 
BOP: bleeding on probing; SD: standard deviation
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Table 2. Univariable and multivariable prediction models of PPD change over 12 months
Predictor
Univariable Multivariable
Coef. SE p Coef. SE p
Patient-related factors - - - - - -
Age Years -0.02 0.05 0.73 - - -
Gender
Males Ref. - - - - -
Females -0.09 0.38 0.80 - - -
Disease extent
Localized Ref. - - Ref. - -
Generalized -0.42 0.45 0.12 -0.58 0.28 0.04
Smoking status
Nonsmokers Ref. - - - - -
Smokers 0.002 0.33 0.99 - - -
Antibiotic use
Placebo Ref. - - Ref. - -
Azithromycin -0.43 0.38 0.24 -0.49 0.24 0.04
Tooth-related factors
Tooth type
Molars Ref. - - Ref. - -
Non-molars -0.69 0.20 0.001 -0.49 0.16 0.002
Visible plaque
Present Ref. - - - - -
Absent -0.80 0.17 <0.001 - - -
Baseline PPD 
4-6 mm Ref. - - Ref. - -
≥7 mm 1.39 0.14 <0.001 1.32 0.12 <0.001
Time
Baseline Ref. - - Ref. -
3 months -2.32 0.22 <0.001 -2.31 0.22 <0.001
6 months -2.60 0.29 <0.001 -2.59 0.29 <0.001
9 months -2.45 0.24 <0.001 -2.45 0.24 <0.001
12 months -2.41 0.25 <0.001 -2.42 0.25 <0.001
PPD: periodontal probing depth; Coef.: coefficient; SE: standard error; Ref.: reference category
Figure 2. Periodontal probing depth over 12 months, according to different predictors (a: disease extent; b: antibiotic use; c: 
tooth type; d: baseline PPD)
Baseline 3 months 6 months 9 months 12 months
Baseline 3 months 6 months 9 months 12 months
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Smoking is considered a major risk factor of 
periodontitis.14 Smoking is also a well-known predictor 
of poor response to periodontal therapy,15 but few 
studies have further demonstrated that smoking 
negatively impacts treatment outcomes in subjects 
with AgP.6,9 In the present study, smoking did not 
show a significant effect on the non-surgical treatment 
outcome of AgP. However, only 5 of the subjects 
(or 21%) were smokers, and this may have mitigated 
the effect of this variable in this study.
Although it is well-established that good plaque 
control is important for periodontal treatment 
success,16 scant data exist regarding its impact on 
AgP treatment. Recent studies suggest that local 
factors and poor oral hygiene are associated with 
AgP.2 The findings of the present study support 
the importance of adequate oral hygiene in the 
management of AgP. Absence of plaque at tooth 
sites was a significant predictor of higher CA gain 
and BOP reduction.
Table 3. Univariable and multivariable prediction models of CA level change over 12 months.
Predictor
Univariable Multivariable
Coef. SE p Coef. SE p
Patient-related factors
Age Years 0.03 0.09 0.77 - - -
Gender
Males Ref. - - - - -
Females 0.13 0.47 0.79 - - -
Disease extent
Localized Ref. - - - - -
Generalized 0.08 0.50 0.87 - - -
Smoking status
Nonsmokers Ref. - - -
Smokers 0.31 0.38 0.42 - - -
Antibiotic use
Placebo Ref. - - - - -









Present Ref. - - Ref - -
Absent -0.70 0.13 <0.001 -0.22 0.11 0.04
Baseline PPD 
4-6 mm Ref. - - Ref - -
≥7 mm 1.38 0.20 <0.001 1.36 0.20 <0.001
Time
Baseline Ref - - Ref. - -
3 months -1.25 0.18 <0.001 -1.16 0.19 <0.001
6 months -1.56 0.19 <0.001 -1.49 0.19 <0.001
9 months -1.43 0.20 <0.001 -1.37 0.20 <0.001
12 months -1.40 0.18 <0.001 -1.33 0.19 <0.001
PPD: periodontal probing depth; Coef.: coefficient; SE: standard error; Ref.: reference category
Figure 3. Clinical attachment level over 12 months, according to different predictors (a: visible plaque; b: baseline PPD).
Baseline 3 months 6 months 9 months 12 months
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Table 4. Univariable and multivariable prediction models of BOP change over 12 months.
Predictor -
Univariable Multivariable
Coef. SE p Coef. SE p
Patient-related factors
Age Years -0.001 0.01 0.82 - - -
Gender Male Ref. - - - - -
Female 0.009 0.05 0.86 - - -
Disease extent Localized Ref. - - - - -
Generalized -0.04 0.05 0.43 - - -
Smoking status Nonsmokers Ref. - - - - -
Smokers -0.02 0.04 0.57 - - -
Antibiotic use Placebo Ref. - - Ref. - -
Azithromycin -0.13 0.04 0.002 -0.14 0.04 0.001
Tooth-related factors
Tooth type Molars Ref. - - Ref.
Non-molars -0.06 0.02 0.001 -0.05 0.02 0.01
Visible plaque Present Ref. - - Ref. - -
Absent -0.21 0.02 <0.001 -0.06 0.02 0.002
Baseline PPD 4-6 mm Ref. - - Ref. - -
≥7 mm 0.08 0.02 <0.001 0.07 0.02 <0.001
Time
Baseline Ref. - - Ref. - -
3 months -0.48 0.03 <0.001 -0.46 0.03 <0.001
6 months -0.53 0.03 <0.001 -0.51 0.03 <0.001
9 months -0.47 0.03 <0.001 -0.45 0.03 <0.001
12 months -0.45 0.03 <0.001 -0.43 0.03 <0.001
PPD: periodontal probing depth; Coef.: coefficient; SE: standard error; Ref.: reference category
Table 5. Multivariable GEE models# of the presence of various bacterial species at baseline as predictors of CA loss, PPD and 
BOP changes over 12 months.
Predictor
CA loss* PPD** BOP***
Coef. SE p Coef. SE p Coef. SE p
P. gingivalis 0.40 0.40 0.32 0.17 0.24 0.70 0.02 0.04 0.55
T. forsythia 0.47 0.36 0.19 0.01 0.22 0.98 -0.002 0.04 0.96
T. denticola 0.22 0.56 0.70 -0.12 0.38 0.75 0.04 0.05 0.42
A. actinomycetemcomitans -0.38 0.43 0.37 -0.43 0.32 0.18 -0.04 0.05 0.46
P. micra 0.35 0.38 0.36 -0.13 0.23 0.58 0.02 0.04 0.96
P. intermedia 0.29 0.40 0.47 -0.16 0.28 0.58 0.01 0.04 0.75
Red complex
1 species Ref. Ref. Ref.
2 species 0.10 0.53 0.84 -0.11 0.32 0.74 -0.05 0.04 0.26
3 species 0.78 0.33 0.02 0.17 0.33 0.60 0.02 0.05 0.63
#Each bacterial species was evaluated in separate models for CA loss, PPD and BOP
*Adjusted for plaque, time and baseline PPD
** Adjusted for time, antibiotic use, tooth type, disease extent and baseline PPD
*** Adjusted for time, antibiotic use, plaque, tooth type and baseline PPD
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The benefits of the adjunctive use of antibiotics in 
the treatment of destructive periodontal diseases have 
been demonstrated.17,18 However, the efficacy of classic 
chemotherapeutic agents has been influenced by their 
complex dosing schedule, low compliance, development 
of bacterial resistance, and other side effects.17 In 
contrast, azithromycin has a convenient dosing 
schedule, thus potentially increasing compliance,19 
and is effective against major periodontopathogens.20,21 
The efficacy of adjunctive azithromycin in the non-
surgical treatment of AgP was first reported in 2008.11 
In the present study, azithromycin showed more 
favorable treatment outcomes for PPD and BOP in 
multivariable prediction models.
Periodontal treatment of molars is more complex than 
that of single-rooted teeth. In AgP patients, molars are 
the most frequently lost teeth.8 In this study, non-molars 
had a higher PPD and BOP reduction than molars, 
whereas CA level changes were not different by tooth 
type. These findings are in agreement with Baumer et al.,6 
who reported higher tooth loss rates in molars after 
periodontal therapy. In contrast, Hughes et al.9 did not 
find any significant differences in treatment response 
between single- and multi-rooted teeth.
In this analysis, deep pockets at baseline were 
associated with a smaller decrease in PPD and 
a higher CA loss than sites with moderate PPD. 
This finding could seem counterintuitive, since it 
has been demonstrated that deep pockets have a 
higher potential for improvement.10 The reason could 
be that final mean PPD and CA loss was still higher 
for teeth with initially deep versus moderate pockets 
(3.6 mm and 4.6 mm, respectively). Thus, although 
greater improvement is likely to be achieved in teeth 
with deeper pockets, these teeth will still present the 
worst post-treatment parameters.
The presence of high proportions of putative 
periodontal pathogens, such as the red complex 
species (P. gingivalis, T. forsythia and T. denticola) and 
A. actinomycetemcomitans, has been associated with 
the progression of clinical attachment loss; therefore, 
failure to reduce specific pathogens may lead to 
disease recurrence.7,22,23 In the current investigation, 
the presence of all three members of the red complex 
at baseline, adjusted for other factors, was associated 
with a higher CA loss over the 12 months after 
treatment. In interpreting these data, one should be 
careful to take into consideration the microbiological 
assessment applied, namely a pooled subgingival 
sample of each individual’s biofilm, which assessed the 
presence/absence of bacteria at a specific threshold for 
each sample pooled. Nonetheless, the present findings 
indicate that identification of the microbiological 
profile of AgP patients before treatment has a possible 
clinical application.
A possible shortcoming of this study was the 
relatively small number of individuals. Consequently, 
some variables could have been overlooked, because 
of the restrictions in the sample size. In other words, 
some predictors may not have demonstrated significant 
associations that could have been found if the sample 
were larger, one example being smoking; clinicians 
should keep this in mind when interpreting the 
findings.  Nevertheless, it is expected that future studies 
with AgP patients will present with fewer individuals, 
due to the lower AgP prevalence in the population, 
compared with other forms of periodontitis.24 Studies 
evaluating different types of periodontal interventions 
in AgP patients have also used sample sizes similar 
to those of the present randomized trial.25,26,27
Future prospects for research in this field include 
studies with longer follow-up periods and larger 
sample sizes. The new information provided in this 
study also highlights the importance of multivariable 
analyses in clinical trial testing interventions for AgP, in 
order to account for a possible confounding bias of the 
predictors detected herein. From a clinical perspective, 
the present data provide information for the clinical 
management of AgP, aiming to achieve better clinical 
outcomes following non-surgical treatment.
Conclusion
Patient- and tooth-related factors predicting 
better treatment outcomes of AgP included extent of 
periodontitis, use of azithromycin, type of teeth affected, 
plaque, and baseline PPD. The prediction of CA level 
changes was more challenging, and the absence of plaque 
and baseline PPD were the only significant predictors 
of CA gain. The concomitant presence of periodontal 
pathogens of the red complex in the subgingival biofilm 
may indicate challenges in ultimately achieving a 
favorable treatment outcome for AgP.
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